ArticleCureus2022

Assessment of the Safety, Efficacy, and Benefit of Empagliflozin in Patients With Type 2 Diabetes Mellitus (T2DM) and Heart Failure With Reduced Ejection Fraction (HFrEF) at High Risk for Cardiovascular Events.

Ruba Towiargi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.